UNSPSC 51273936: Epinephrine/etidocaine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.

UNSPSC 51273936 Epinephrine/etidocaine is a Commodity code that encompasses pharmaceutical products supplied to state and local health agencies, community health programs, and multi-state purchasing cooperatives. Recent solicitations show state and local governments buying naloxone, generic pharmaceuticals, and over-the-counter products through both direct procurement and cooperative purchasing vehicles. Issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances administering contracts on behalf of dozens of participating state and local entities. The scope spans acute-response medications (naloxone kits for emergency response), generic multi-source pharmaceuticals distributed through authorized wholesalers, and direct-to-manufacturer prescription programs designed to optimize cost and supply efficiency for state employee and Medicaid populations.

Activity is concentrated in Florida and Minnesota, with Texas engaging in preliminary market research through an RFI phase. Recent solicitations include Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the county community health building; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) gathering vendor capabilities for direct-to-manufacturer prescription programs prior to formal RFP issuance; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multi-vendor contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers to participating state and local facilities across Minnesota and Oregon, with contract performance effective July 1, 2026 and a two-year initial term.